Literature DB >> 7884823

Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q.

S Webster1, S O'Barr, J Rogers.   

Abstract

Several lines of evidence now suggest that aggregation of soluble amyloid beta peptide (A beta) into a cross beta sheet configuration may be an important factor in mediating potential neurotoxicity of A beta. Synthetic A beta has been shown to self aggregate in vitro. Here, we demonstrate that coincubation of freshly solubilized A beta with C1q, a complement component known to bind A beta in vitro and to colocalize with A beta in vivo, results in as much as a 7-fold enhancement of A beta aggregation, as well as a 2-4-fold enhancement of beta structure within aggregates. The addition of C1q to preformed A beta aggregates also results in significantly increased resistance to aggregate resolubilization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7884823     DOI: 10.1002/jnr.490390412

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  18 in total

1.  Adenosine 3',5'-cyclic monophosphate increases processing of amyloid precursor protein (APP) to beta-amyloid in neuroblastoma cells without changing APP levels or expression of APP mRNA.

Authors:  A Kumar; F G La Rosa; A R Hovland; W C Cole; J Edwards-Prasad; K N Prasad
Journal:  Neurochem Res       Date:  1999-10       Impact factor: 3.996

2.  Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.

Authors:  L Bergamaschini; S Canziani; B Bottasso; M Cugno; P Braidotti; A Agostoni
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

3.  Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide.

Authors:  S Webster; B Bonnell; J Rogers
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

4.  CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE.

Authors:  Jorge Ghiso; Yasushi Tomidokoro; Tamas Revesz; Blas Frangione; Agueda Rostagno
Journal:  Hirosaki Igaku       Date:  2010-07-08

5.  Pharmacotherapy in the treatment of Alzheimer's disease: an update.

Authors:  Brian E Leonard
Journal:  World Psychiatry       Date:  2004-06       Impact factor: 49.548

6.  Do nonsteroidal anti-inflammatory drugs have a protective effect against dementia?

Authors:  F L Van Muiswinkel; P Eikelenboom
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

Review 7.  Amyloidosis associated with cerebral amyloid angiopathy: cell signaling pathways elicited in cerebral endothelial cells.

Authors:  Jorge Ghiso; Silvia Fossati; Agueda Rostagno
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 8.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

9.  C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-β neurotoxicity.

Authors:  Marie E Benoit; Michael X Hernandez; Minhan L Dinh; Francisca Benavente; Osvaldo Vasquez; Andrea J Tenner
Journal:  J Biol Chem       Date:  2012-11-13       Impact factor: 5.157

10.  Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease.

Authors:  Maria Isabel Fonseca; Jun Zhou; Marina Botto; Andrea J Tenner
Journal:  J Neurosci       Date:  2004-07-21       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.